Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Protein structures in virtual screening: a case study with CDK2.

Mark P Thomas1, Campbell McInnes, Peter M Fischer

  • 1Cyclacel Ltd., James Lindsay Place, Dundee, DD1 5JJ, UK. mthomas@cyclacel.com

Journal of Medicinal Chemistry
|January 6, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Repurposing Purine Analog Antivirals to Modulate Serum Uric Acid: Evidence From Real-World Data.

Clinical and translational science·2026
Same author

Discovery of Drug-like Inhibitors of the Human Caf1/CNOT7 poly(A)-Selective Nuclease Using Compound Screening.

Biomolecules·2025
Same author

Structural regulation of PLK1 activity: implications for cell cycle function and drug discovery.

Cancer gene therapy·2025
Same author

Overcoming Resistance to FLT3-ITD Therapeutics.

Journal of medicinal chemistry·2024
Same author

Discovery of Substituted 5-(2-Hydroxybenzoyl)-2-Pyridone Analogues as Inhibitors of the Human Caf1/CNOT7 Ribonuclease.

Molecules (Basel, Switzerland)·2024
Same author

A highly potent bi-thiazole inhibitor of LOX rewires collagen architecture and enhances chemoresponse in triple-negative breast cancer.

Cell chemical biology·2024
Same journal

Rational Development of Activatable Prodrugs of the GSTP1 Inhibitor NBDHEX: Turn-On NIR Fluorogenic Drug Delivery with Selective Anticancer Activity.

Journal of medicinal chemistry·2026
Same journal

Recent Highlights in the Discovery and Design of Antibody-Drug Conjugates.

Journal of medicinal chemistry·2026
Same journal

One Face, Three Solutions: Structural Convergence in PD-L1 Inhibition across Antibodies, Macrocycles, and Small Molecules.

Journal of medicinal chemistry·2026
Same journal

A Potent and Selective Quinolone-Based PTPN22 Inhibitor with Improved Immunotherapeutic Activity.

Journal of medicinal chemistry·2026
Same journal

Structure-Based Discovery of (<i>E</i>)- and (<i>Z</i>)-4-Oxobut-2-enoate Derivatives as Novel Covalent Pin1 Inhibitors with Antitumor Activity.

Journal of medicinal chemistry·2026
Same journal

Hybrids of Benzenesulfonamide Oxadiazole Derivatives with Dual CA II and COX-2 Inhibitory Activity Demonstrating Antiglaucoma and Anti-inflammatory Action: Synthesis, In Silico Insights, and In Vitro and In Vivo Bioevaluation.

Journal of medicinal chemistry·2026
See all related articles

Protein structure significantly impacts the accuracy of molecular docking for drug discovery. Researchers found that binding site volume and residue orientation in CDK2 structures greatly influenced whether docking programs like Glide and GOLD reproduced known ligand poses.

Area of Science:

  • Computational chemistry
  • Structural biology
  • Drug discovery

Background:

  • High-throughput docking programs are crucial for identifying potential drug candidates.
  • The accuracy of docking predictions is known to be influenced by protein structure.
  • However, the specific impact of protein structure variations on reproducing known ligand poses is under-explored.

Purpose of the Study:

  • To investigate how different protein structures affect the success rate of reproducing known ligand poses using molecular docking.
  • To identify key structural features that enhance or diminish docking accuracy.

Main Methods:

  • Utilized two popular docking programs, Glide and GOLD.
  • Docked a set of known cyclin-dependent kinase 2 (CDK2) inhibitors with established bound poses.

Related Experiment Videos

  • Tested these ligands against 20 distinct CDK2 protein structures.

    • Main Results:

    • The percentage of correctly reproduced ligand poses varied widely, ranging from 0.3% to 96.2%.
    • Performance was highly dependent on both the docking program and the specific CDK2 protein structure used.
    • Binding site volume and the orientation of binding site residues were identified as primary determinants of docking success.

    Conclusions:

    • No single protein structure is universally optimal for virtual screening.
    • Certain CDK2 structures offer significantly better performance for reproducing known ligand poses than others.
    • Understanding the influence of protein structure is key to optimizing virtual screening strategies.